FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150871719> ?p ?o ?g. }

• W2150871719 endingPage "2911" @default.
• W2150871719 startingPage "2902" @default.
• W2150871719 abstract "To determine whether the combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen can sensitize human lymphoma to cyclophosphamide.Cytotoxicity assays were conducted to determine if there was any additive or synergistic interaction between the combinations of bortezomib, oblimersen, and cyclophosphamide using a standard trypan blue exclusion assay. Based on these experiments, in vivo experiments in severe combined immunodeficiency beige mice were done using human lymphoma xenografts in which different schedules were explored. Bcl-2 and oblimersen levels were determined in treated tumors, some of which were resected at the end of the in vivo experiment and evaluated pathologically.The results suggest that the combination of bortezomib and oblimersen seem to interact in at least an additive fashion, and that the addition of cyclophosphamide to this drug combination can markedly improve tumor cell kill. In addition, it seems that these drug combinations may be schedule-dependent, with a requirement for oblimersen pretreatment. Animals treated with the triplet drug combination in a schedule-dependent manner experienced pathologic complete regression of disease, which was not observed in other treatment cohorts. The addition of bortezomib also seemed to increase the levels of intracellular oblimersen, which resulted in a marked reduction in Bcl-2. Histologic studies confirmed marked necrosis and caspase-3 activation only in the cohort receiving all three drugs.The use of Bcl-2-directed therapy and a proteasome inhibitor sensitizes human lymphoma cells to cytotoxic drugs like cyclophosphamide. This combination may offer new opportunities for integrating novel targeted therapies with conventional chemotherapy." @default.
• W2150871719 created "2016-06-24" @default.
• W2150871719 creator A5002126535 @default.
• W2150871719 creator A5010259747 @default.
• W2150871719 creator A5010286156 @default.
• W2150871719 creator A5012262072 @default.
• W2150871719 creator A5036224917 @default.
• W2150871719 creator A5039118991 @default.
• W2150871719 creator A5054745917 @default.
• W2150871719 creator A5059110616 @default.
• W2150871719 creator A5062250759 @default.
• W2150871719 creator A5071873190 @default.
• W2150871719 creator A5076577365 @default.
• W2150871719 date "2006-05-01" @default.
• W2150871719 modified "2023-09-25" @default.
• W2150871719 title "The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide" @default.
• W2150871719 cites W1536449496 @default.
• W2150871719 cites W1963899781 @default.
• W2150871719 cites W1967354499 @default.
• W2150871719 cites W1972071205 @default.
• W2150871719 cites W1982595408 @default.
• W2150871719 cites W2024582476 @default.
• W2150871719 cites W2027891144 @default.
• W2150871719 cites W2075576299 @default.
• W2150871719 cites W2082575834 @default.
• W2150871719 cites W2100608938 @default.
• W2150871719 cites W2100888471 @default.
• W2150871719 cites W2116090592 @default.
• W2150871719 cites W2168934491 @default.
• W2150871719 doi "https://doi.org/10.1158/1078-0432.ccr-05-0308" @default.
• W2150871719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16675587" @default.
• W2150871719 hasPublicationYear "2006" @default.
• W2150871719 type Work @default.
• W2150871719 sameAs 2150871719 @default.
• W2150871719 citedByCount "41" @default.
• W2150871719 countsByYear W21508717192012 @default.
• W2150871719 countsByYear W21508717192013 @default.
• W2150871719 countsByYear W21508717192014 @default.
• W2150871719 countsByYear W21508717192015 @default.
• W2150871719 countsByYear W21508717192023 @default.
• W2150871719 crossrefType "journal-article" @default.
• W2150871719 hasAuthorship W2150871719A5002126535 @default.
• W2150871719 hasAuthorship W2150871719A5010259747 @default.
• W2150871719 hasAuthorship W2150871719A5010286156 @default.
• W2150871719 hasAuthorship W2150871719A5012262072 @default.
• W2150871719 hasAuthorship W2150871719A5036224917 @default.
• W2150871719 hasAuthorship W2150871719A5039118991 @default.
• W2150871719 hasAuthorship W2150871719A5054745917 @default.
• W2150871719 hasAuthorship W2150871719A5059110616 @default.
• W2150871719 hasAuthorship W2150871719A5062250759 @default.
• W2150871719 hasAuthorship W2150871719A5071873190 @default.
• W2150871719 hasAuthorship W2150871719A5076577365 @default.
• W2150871719 hasBestOaLocation W21508717191 @default.
• W2150871719 hasConcept C126322002 @default.
• W2150871719 hasConcept C150903083 @default.
• W2150871719 hasConcept C203014093 @default.
• W2150871719 hasConcept C207001950 @default.
• W2150871719 hasConcept C27740335 @default.
• W2150871719 hasConcept C2776364478 @default.
• W2150871719 hasConcept C2776694085 @default.
• W2150871719 hasConcept C2776755627 @default.
• W2150871719 hasConcept C2777478702 @default.
• W2150871719 hasConcept C2778367456 @default.
• W2150871719 hasConcept C2779338263 @default.
• W2150871719 hasConcept C502942594 @default.
• W2150871719 hasConcept C55493867 @default.
• W2150871719 hasConcept C71924100 @default.
• W2150871719 hasConcept C86803240 @default.
• W2150871719 hasConcept C98274493 @default.
• W2150871719 hasConceptScore W2150871719C126322002 @default.
• W2150871719 hasConceptScore W2150871719C150903083 @default.
• W2150871719 hasConceptScore W2150871719C203014093 @default.
• W2150871719 hasConceptScore W2150871719C207001950 @default.
• W2150871719 hasConceptScore W2150871719C27740335 @default.
• W2150871719 hasConceptScore W2150871719C2776364478 @default.
• W2150871719 hasConceptScore W2150871719C2776694085 @default.
• W2150871719 hasConceptScore W2150871719C2776755627 @default.
• W2150871719 hasConceptScore W2150871719C2777478702 @default.
• W2150871719 hasConceptScore W2150871719C2778367456 @default.
• W2150871719 hasConceptScore W2150871719C2779338263 @default.
• W2150871719 hasConceptScore W2150871719C502942594 @default.
• W2150871719 hasConceptScore W2150871719C55493867 @default.
• W2150871719 hasConceptScore W2150871719C71924100 @default.
• W2150871719 hasConceptScore W2150871719C86803240 @default.
• W2150871719 hasConceptScore W2150871719C98274493 @default.
• W2150871719 hasIssue "9" @default.
• W2150871719 hasLocation W21508717191 @default.
• W2150871719 hasLocation W21508717192 @default.
• W2150871719 hasOpenAccess W2150871719 @default.
• W2150871719 hasPrimaryLocation W21508717191 @default.
• W2150871719 hasRelatedWork W1510436441 @default.
• W2150871719 hasRelatedWork W1732928399 @default.
• W2150871719 hasRelatedWork W1989669927 @default.
• W2150871719 hasRelatedWork W2241764418 @default.
• W2150871719 hasRelatedWork W2321752808 @default.
• W2150871719 hasRelatedWork W2385905373 @default.
• W2150871719 hasRelatedWork W2564340835 @default.
• W2150871719 hasRelatedWork W2979589406 @default.

• next